A clinical trial published in JAMA Internal Medicine indicates that two repurposed drugs—low-dose naltrexone and famotidine—show modest, short-term benefits in reducing fatigue for patients with long COVID. While the study suggests these medications may help manage specific symptoms, researchers emphasize that the improvements were limited and did not represent a cure for the condition.
Clinical Trial Findings on Naltrexone and Famotidine
Researchers at the RECOVER Initiative, a research program funded by the National Institutes of Health (NIH), conducted a phase 2 clinical trial to evaluate potential treatments for long COVID. The study focused on whether medications already approved for other conditions could be repurposed to address persistent symptoms such as brain fog, fatigue, and exercise intolerance.
According to the study results, participants who took low-dose naltrexone—commonly used to treat opioid and alcohol dependence—or famotidine—a standard treatment for heartburn and acid reflux—reported minor improvements in fatigue scores over the course of the trial. However, these benefits were statistically modest and did not persist significantly after the treatment period concluded. The investigators noted that neither drug provided a dramatic reversal of the complex, multisystem symptoms that characterize long COVID.
Understanding Long COVID Treatment Challenges
Long COVID remains a diagnostic and therapeutic challenge because it encompasses a wide range of symptoms, including cognitive impairment, dyspnea, and profound exhaustion. Because the underlying biological mechanisms—which may include immune dysregulation, viral persistence, or inflammation—remain under active investigation, there is currently no FDA-approved medication specifically for the condition.
The use of repurposed drugs is a common strategy in early-stage clinical research. By using medications with established safety profiles, researchers can more quickly determine if these agents might modulate the inflammatory pathways suspected to drive long COVID. The NIH-funded trial serves as a foundational step in identifying which pharmacological targets warrant further, larger-scale study.
Important Considerations for Patients
Medical professionals advise that patients should not initiate off-label use of naltrexone or famotidine for long COVID without direct supervision from a healthcare provider. While these drugs are generally considered safe for their original indications, their efficacy and safety profile for long COVID patients require further validation in phase 3 trials.
The RECOVER Initiative continues to enroll participants in various trials to explore other potential interventions. For those living with long COVID, experts recommend focusing on symptom management through pacing, physical therapy, and multidisciplinary care coordinated by specialized post-COVID clinics.
Key Takeaways
- Modest Benefit: The trial found that low-dose naltrexone and famotidine offered only minor, short-term relief for fatigue.
- Not a Cure: Neither medication demonstrated the ability to resolve the underlying causes of long COVID.
- Research Context: These findings come from a phase 2 trial under the NIH-funded RECOVER Initiative, which aims to identify viable treatments through rigorous scientific testing.
- Medical Supervision: Patients should consult their physicians before attempting to use these or any other medications for off-label purposes related to long COVID.